Interchangeability Designation Still Widely Debated, Prescribers Hesitant About Biosimilars
The FDA is the only authority that can designate a biosimilar as interchangeable with its reference product, which requires that the product has similar clinical results for the same indication.
Source: pharmacytimes.com